Immune Design is a clinical stage company with next-generation, in vivo approaches designed to enable the immune system’s natural ability to create tumor-specific cytotoxic T-cells in order to combat cancer. Immune Design is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which have the potential to treat a broad patient population as individual therapies or in combination with other immuno-oncology agents. Immune Design’s lead product candidates, CMB305 and G100, employ an antigen-specific and an antigen-agnostic approach, respectively.